SP1.9 - Management of cutaneous abscesses and infected sebaceous cysts using inhaled methoxyflurane Penthrox®: a 12 month prospective observational study

Abstract Aims Incision and drainage of abscesses contribute a significant burden upon emergency general surgical theatres. The purpose of this study was to look at the safety and effectiveness of incision and drainage using inhaled methoxyflurane (Penthrox®) to reduce reliance upon surgical theatres and provide an effective alternative to local anaesthetic. Methods After a successful pilot of 20 patients, adults with ‘simple’ abscesses were enrolled over a 12-month period and given inhaled methoxyflurane for ward-based incision and drainage. Pilonidal and perianal abscesses, patients with ASA ≥3 and abscesses greater than 5cm in size were excluded. Length of admission and outcomes at 1 week, 1 month and 3 months post procedure were compared to previously audited data on simple abscess drainage in theatre to determine safety, efficacy and cost-savings. Results 130 patients had an abscess drained using Penthrox® inhaled analgesia. 93.8% (122/130) had successful drainage with a mean admission time of 99 minutes. Eight patients reattended for further treatment (3<3 months, 3<1 month and 2<1 week); two patients required antibiotics and five required further drainage. Patients taken to theatre spent on average 34.5 hours in hospital compared to 1.65 hours for those performed using Penthrox®. A patient feedback tool captured very positive comments with no negative experiences recorded. Conclusion Penthrox® is a safe, effective analgesic for the incision and drainage of simple abscesses and patient experience is overwhelmingly positive. In addition, it significantly reduces the burden on emergency theatres and the hospital bed-base with an estimated minimum saving of £1704 per patient.